The eatertainment brand saw same-store sales fall 7.7% last quarter, and failed to maintain a leverage ratio required by a financing covenant.

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report), with a price ...

When we spoke three years ago, your research was focused on the shopping center, net lease and health care subsectors. Is there anything new or different about your coverage universe here in 2025? Mr.

BTIG analyst Janine Stichter raised the firm’s price target on Warby Parker (WRBY) to $30 from $22 and keeps a Buy rating on the shares ahead ...

BTIG lowered the firm’s price target on NeoGenomics (NEO) to $17 from $18 and keeps a Buy rating on the shares. Q4 results came in light “at an ...

Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...

Elon Musk’s 97-billion-dollar bid for OpenAI was soundly rejected by the artificial intelligence startup, which said the company “is not for sale.” ...

Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule. Event: BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference 2025 ...

The oft-maligned skinny jean has crept back onto the runway and is headed for a comeback as soon as this fall.